Search

We address an open problem in the philosophy of artificial intelligence (AI): how to justify the epistemic attitudes we have towards the trustworthiness of AI systems. The problem is important, as providing reasons to believe that AI systems are worthy of trust is key to appropriately rely on these systems in human-AI interactions. In our approach, we consider the trustworthiness of an AI as a time-relative, composite property of the system with two distinct facets. One is the actual trustworthiness of the AI and the other is the perceived trustworthiness of the system as assessed by its users while interacting with it. We show that credences, namely, beliefs we hold with a degree of confidence, are the appropriate attitude for capturing the facets of the trustworthiness of an AI over time. Then, we introduce a reliabilistic account providing justification to the credences in the trustworthiness of AI, which we derive from Tang’s probabilistic theory of justified credence. Our account stipulates that a credence in the trustworthiness of an AI system is justified if and only if it is caused by an assessment process that tends to result in a high proportion of credences for which the actual and perceived trustworthiness of the AI are calibrated. This approach informs research on the ethics of AI and human-AI interactions by providing actionable recommendations on how to measure the reliability of the process through which users perceive the trustworthiness of the system, investigating its calibration to the actual levels of trustworthiness of the AI as well as users’ appropriate reliance on the system. [ABSTRACT FROM AUTHOR]

The aim of this paper is to delve into the epistemological challenge surrounding the qualitative and quantitative aspects of belief and credence through a decision-theoretic framework: belief emerges as a cognitive process balancing the urge for information and the fear of error. The first part is primarily historical, and delves into the philosophy of science and its concern about the acceptance of probabilistic hypothesis. In the second part, the focus shifts from the philosophy of science to contemporary epistemology, specifically the rationality of belief and credence. The main outcome of this paper lies in highlighting how the decision-theoretic approach illuminates the nature of belief rationality, exploring the connection between belief and credence, the context-dependent nature of belief, and the significance of deductive closure as rational requirements. [ABSTRACT FROM AUTHOR]

Abstract The aim of this paper is to delve into the epistemological challenge surrounding the qualitative and quantitative aspects of belief and credence through a decision-theoretic framework: belief emerges as a cognitive process balancing the urge for information and the fear of error. The first part is primarily historical, and delves into the philosophy of science and its concern about the acceptance of probabilistic hypothesis. In the second part, the focus shifts from the philosophy of science to contemporary epistemology, specifically the rationality of belief and credence. The main outcome of this paper lies in highlighting how the decision-theoretic approach illuminates the nature of belief rationality, exploring the connection between belief and credence, the context-dependent nature of belief, and the significance of deductive closure as rational requirements.

Previous literature supports the importance of corporate social responsibility (CSR) by demonstrating its effects on various aspects of firm performance. However, the extent to which CSR contributes to social well-being, its original objective, has rarely been examined. The current research investigates the impact of customers’ perceived CSR of service firms on customer happiness. Two studies confirm our proposition that perceived CSR increases customer happiness by enhancing perceptions of warmth and competence associated with the service company. Furthermore, we examine how the type of service moderates this effect. Specifically, we find that the indirect effects of CSR on customer happiness through perceptions of warmth and competence are stronger for credence services than for experience services. This research makes theoretical contributions to the literature on CSR, happiness, and service, and offers practical implications for marketing tactics, including fostering long-term customer relationships and monitoring the effectiveness of CSR activities and corporate budget allocations.

BackgroundTo summarize the four recent sodium-glucose cotransporter 2 inhibitor (SGLT2i) trials: Dapagliflozin Effect on CardiovascuLAR Events (DECLARE-TIMI 58), CANagliflozin CardioVascular Assessment Study (CANVAS) Program, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME), Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), and explore the potential determinants for their cardiovascular, renal, and safety outcomes.ResultsThe composite renal outcome event rates per 1000 patient-years for drug and placebo, as well as the corresponding relative risk reductions, were 3.7, 7.0, 47%; 5.5, 9.0, 40%; 6.3, 11.5, 46%; 43.2, 61.2, 30% for DECLARE-TIMI 58, CANVAS, EMPA-REG OUTCOME, and CREDENCE, respectively (event definitions varied across trials). The major adverse cardiovascular (CV) event rates per 1000 patient-years for drug and placebo, as well as the corresponding relative risk reductions, were 22.6, 24.2, 7%; 26.9, 31.5, 14%; 37.4, 43.9, 14%; 38.7, 48.7, 20% for DECLARE-TIMI 58, CANVAS, EMPA-REG OUTCOME, and CREDENCE, respectively. DECLARE-TIMI 58 had the fewest cardiorenal events and CREDENCE the most. These differences were presumably due to varying inclusion criteria resulting in DECLARE-TIMI 58 having the best baseline renal filtration function and CREDENCE the worst (mean estimated glomerular filtration rate 85.2, 76.5, 74, 56.2 mL/min/1.73 m2 for DECLARE-TIMI 58, CANVAS, EMPA-REG OUTCOME, and CREDENCE, respectively). Additionally, CREDENCE had considerably higher rates of albuminuria (median urinary albumin-creatinine ratios (UACR) were 927, 12.3, and 13.1 mg/g for CREDENCE, CANVAS, and DECLARE-TIMI 58, respectively; EMPA-REG OUTCOME had 59.4% UACR  30-300, 11.0% UACR > 300 mg/g).ConclusionsDapagliflozin, empagliflozin, and canagliflozin have internally and externally consistent and biologically plausible class effects on cardiorenal outcomes. Baseline renal filtration function and degree of albuminuria are the most significant indicators of risk for both CV and renal events. Thus, these two factors also anticipate the greatest clinical benefit for SGLT2i.

Food credence attributes (e.g., food safety, organic, and carbon neutral production methods) are quality characteristics of products that cannot be assessed by buyers at the point of sale without additional information (e.g., certification labels). Hence, the ability to access credence attributes of a particular product can result in a situation termed as asymmetric distributed information among supply chain stakeholders (e.g., producers, processors, wholesalers, retailers, consumer) where one party of a market transaction is in possession of more information about a product than the other party. This situation can lead to potential inefficiencies, e.g., misinformation, risk of food borne illness, or opportunistic behavior such as fraud. The present study sought to develop a conceptual framework that describes a) the motivation for key stakeholders to participate in the market for food credence attributes, b) the type of food credence attributes that key stakeholders provide, and c) current mechanisms to address the issue of information asymmetry among the stakeholders in the food system. The study was conducted using an integrative literature review. The developed framework consists of two components: a) the food supply chain and b) the attribute assurance system among which multiple links exist. The findings suggest that retailers, processors, NGOs, and government authorities are influential stakeholders within the supply chain of food credence attributes by imposing food quality standards which can address information asymmetry among food actors. While the credence attribute assurance system (e.g., food standards, third party food attribute assurance providers) can potentially address the issue of asymmetric information among market stakeholders, a range of issues remain. These include food standards as a potential market entry barrier for food producers and distributors, limited food standard harmonization, and communication challenges of food attribute assurance (e.g., consumers' signal processing, signal use and trust). The syntheses presented in this study contributes to stakeholders' (e.g., supply chain actors, scientists, policy makers) improved understanding about the components of the credence food system and their integration as well as the drivers for change in this system. [ABSTRACT FROM AUTHOR]

The series of the cardiovascular outcome trails have demonstrated the nephroprotective properties of the gliflozins. Canagliflozin in the CREDENCE, which was the first study with a primary focus on the evaluation of the nephroprotective properties of gliflozin, have demonstrated the possibility to slow the progression of the renal disease. The paper summarizes the additional data from the CREDENCE trail: assessment of the efficacy of canagliflozin by initial eGFR; efficacy in individuals with GFR

ABSTRACT Aims/Introduction The sodium–glucose cotransporter 2 inhibitor, canagliflozin, reduced kidney failure and cardiovascular events in the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial. We carried out a post‐hoc analysis to evaluate the efficacy and safety of canagliflozin in a subgroup of participants in East and South‐East Asian (EA) countries who are at high risk of renal complications. Materials and Methods Participants with an estimated glomerular filtration rate of 30 to 300–5,000 mg/g were randomized to 100 mg of canagliflozin or a placebo. The effects of canagliflozin treatment on pre‐specified efficacy and safety outcomes were examined using Cox proportional hazards regression between participants from EA countries (China, Japan, Malaysia, the Philippines, South Korea and Taiwan) and the remaining participants. Results Of 4,401 participants, 604 (13.7%) were from EA countries; 301 and 303 were assigned to the canagliflozin and placebo groups, respectively. Canagliflozin lowered the risk of primary outcome (composite of end‐stage kidney disease, doubling of serum creatinine level, or renal or cardiovascular death) in EA participants (hazard ratio 0.54, 95% confidence interval 0.35–0.84). The effects of canagliflozin on renal and cardiovascular outcomes in EA participants were generally similar to those of the remaining participants. Safety outcomes were similar between the EA and non‐EA participants. Conclusions In the CREDENCE trial, the risk of renal and cardiovascular events was safely reduced in participants from EA countries at high risk of renal events.

Background The nonsteroidal mineralocorticoid receptor antagonist finerenone and the sodium–glucose cotransporter-2 inhibitor (SGLT-2i) canagliflozin reduce cardiorenal risk in albuminuric patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). At first glance, the results of Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) (ClinicalTrials.gov , NCT02540993) and Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) appear disparate. In FIDELIO-DKD, the primary endpoint had an 18% [95% confidence interval (CI) 7–27] relative risk reduction; in CREDENCE, the primary endpoint had a 30% (95% CI 18–41) relative risk reduction. Unlike CREDENCE, the FIDELIO-DKD trial included patients with high albuminuria but excluded patients with symptomatic heart failure with reduced ejection fraction. The primary endpoint in the FIDELIO-DKD trial was kidney specific and included a sustained decline in the estimated glomerular filtration rate (eGFR) of ≥40% from baseline. In contrast, the primary endpoint in the CREDENCE trial included a sustained decline in eGFR of ≥57% from baseline and cardiovascular (CV) death. This post hoc exploratory analysis investigated how differences in trial design—inclusion/exclusion criteria and definition of primary outcomes—influenced observed treatment effects. Methods Patients from FIDELIO-DKD who met the CKD inclusion criteria of the CREDENCE study (urine albumin: creatinine ratio >300–5000 mg/g and an eGFR of 30–<90 mL/min/1.73 m2 at screening) were included in this analysis. The primary endpoint was a cardiorenal composite (CV death, kidney failure, eGFR decrease of ≥57% sustained for ≥4 weeks or renal death). Patients with symptomatic heart failure with reduced ejection fraction were excluded from FIDELIO-DKD. Therefore, in a sensitivity analysis, we further adjusted for the baseline prevalence of heart failure. Results Of 4619/5674 (81.4%) patients who met the subgroup inclusion criteria, 49.6% were treated with finerenone and 50.4% received placebo. The rate of the cardiorenal composite endpoint was 43.9/1000 patient-years with finerenone compared with 59.5/1000 patient-years with placebo. The relative risk was significantly reduced by 26% with finerenone versus placebo [hazard ratio (HR) 0.74 (95% CI 0.63–0.87)]. In CREDENCE, the rate of the cardiorenal composite endpoint was 43.2/1000 patient-years with canagliflozin compared with 61.2/1000 patient-years with placebo; a 30% risk reduction was observed with canagliflozin [HR 0.70 (95% CI 0.59–0.82)]. Conclusions This analysis highlights the pitfalls of direct comparisons between trials. When key differences in trial design are considered, FIDELIO-DKD and CREDENCE demonstrate cardiorenal benefits of a similar magnitude. [ABSTRACT FROM AUTHOR]

Network analysis of Word of Mouth (WOM) examines how customers exchange opinions within their social networks. Compared to standard survey questions, which typically measure the likelihood to recommend, the network approach provides more metrics (e.g., average path length, clustering coefficient, density, average degree) that can be used to diagnose customer chatter. Unfortunately, traditional WOM has not benefitted from network analysis, which usually is applied to online WOM due to the availability of stored data. Despite the pervasiveness of online WOM, recent commercial reports reveal that traditional WOM still surpasses online WOM by a large margin. Traditional WOM is also perceived as more trustworthy and persuasive than online WOM. Thus, given the heavy reliance on traditional WOM and the advances made in network analysis that deal with online WOM, the main purpose of this study is to demonstrate that network analysis is a viable option for gaining insights in traditional WOM. This is the first study to utilize a survey method for collecting WOM network data for a wide range of products, which allows a direct comparison of their network structures. While network analysis may be more demanding on the researcher and the respondents, as the study illustrates, it also is more diagnostic than a standard survey. The main study utilized network analysis by using an alter-alter method, which was used to map the WOM networks structures for multiple products. Specifically, we examined the WOM networks structure as a function of product type (search, experience, and credence products) and opinion valence (positive vs. negative). The results reveal that WOM networks are affected primarily by product type. People are most likely to share opinions about experience products, followed by opinions about search products, and least likely to talk about credence products. The effect of opinion valence is limited. These findings are of practical relevance because they show that WOM can be managed by including search, experience, or credence qualities in promotional messages. This study also is the first to compare WOM networks to the existing social network, which can serve as a benchmark for evaluating WOM campaigns. The results reveal that for most products, people do not utilize all of their social connections for WOM, but there are exceptions, such as sharing a positive opinion about a movie, where WOM chatter can exceed the social network. Introducing a new method for studying traditional WOM also brings new research questions, and the study concludes with limitations and future research directions. Overall, the conclusion is that network analysis is a viable technique for studying traditional WOM. [ABSTRACT FROM AUTHOR]

This essay discusses the difficulty to reconcile two paradigms about beliefs: the binary or categorical paradigm of yes/no beliefs and the probabilistic paradigm of degrees of belief. The possibility for someone to hold beliefs of both types simultaneously is challenged by the lottery paradox, and more recently by a general impossibility theorem by Dietrich and List. The nature, relevance, and implications of the tension are explained and assessed. [ABSTRACT FROM AUTHOR]

Abstract The 5th Cardiovascular Outcome Trial (CVOT) Summit was held in Munich on October 24th–25th, 2019. As in previous years, this summit served as a reference meeting for in-depth discussions on the topic of recently completed and presented CVOTs. This year, focus was placed on the CVOTs CAROLINA, CREDENCE, DAPA-HF, REWIND, and PIONEER-6. Trial implications for diabetes management and the impact on new treatment algorithms were highlighted for diabetologists, cardiologists, endocrinologists, nephrologists, and general practitioners. Discussions evolved from CVOTs to additional therapy options for heart failure (ARNI), knowledge gained for the treatment and prevention of heart failure and diabetic kidney disease in populations with and without diabetes, particularly using SGLT-2 inhibitors and GLP-1 receptor agonists. Furthermore, the ever increasing impact of CVOTs and substances tested for primary prevention and primary care was discussed. The 6th Cardiovascular Outcome Trial Summit will be held in Munich on October 29th–30th, 2020 ( https://www.cvot.org ).

Aims/Introduction: The sodium–glucose cotransporter 2 inhibitor, canagliflozin, reduced kidney failure and cardiovascular events in the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial. We carried out a post‐hoc analysis to evaluate the efficacy and safety of canagliflozin in a subgroup of participants in East and South‐East Asian (EA) countries who are at high risk of renal complications. Materials and Methods: Participants with an estimated glomerular filtration rate of 30 to <90 mL/min/1.73 m2 and urinary albumin‐to‐creatinine ratio of >300–5,000 mg/g were randomized to 100 mg of canagliflozin or a placebo. The effects of canagliflozin treatment on pre‐specified efficacy and safety outcomes were examined using Cox proportional hazards regression between participants from EA countries (China, Japan, Malaysia, the Philippines, South Korea and Taiwan) and the remaining participants. Results: Of 4,401 participants, 604 (13.7%) were from EA countries; 301 and 303 were assigned to the canagliflozin and placebo groups, respectively. Canagliflozin lowered the risk of primary outcome (composite of end‐stage kidney disease, doubling of serum creatinine level, or renal or cardiovascular death) in EA participants (hazard ratio 0.54, 95% confidence interval 0.35–0.84). The effects of canagliflozin on renal and cardiovascular outcomes in EA participants were generally similar to those of the remaining participants. Safety outcomes were similar between the EA and non‐EA participants. Conclusions: In the CREDENCE trial, the risk of renal and cardiovascular events was safely reduced in participants from EA countries at high risk of renal events. [ABSTRACT FROM AUTHOR]

Food credence attributes (e.g., food safety, organic, and carbon neutral production methods) are quality characteristics of products that cannot be assessed by buyers at the point of sale without additional information (e.g., certification labels). Hence, the ability to access credence attributes of a particular product can result in a situation termed as asymmetric distributed information among supply chain stakeholders (e.g., producers, processors, wholesalers, retailers, consumer) where one party of a market transaction is in possession of more information about a product than the other party. This situation can lead to potential inefficiencies, e.g., misinformation, risk of food borne illness, or opportunistic behavior such as fraud. The present study sought to develop a conceptual framework that describes a) the motivation for key stakeholders to participate in the market for food credence attributes, b) the type of food credence attributes that key stakeholders provide, and c) current mechanisms to address the issue of information asymmetry among the stakeholders in the food system. The study was conducted using an integrative literature review. The developed framework consists of two components: a) the food supply chain and b) the attribute assurance system among which multiple links exist. The findings suggest that retailers, processors, NGOs, and government authorities are influential stakeholders within the supply chain of food credence attributes by imposing food quality standards which can address information asymmetry among food actors. While the credence attribute assurance system (e.g., food standards, third party food attribute assurance providers) can potentially address the issue of asymmetric information among market stakeholders, a range of issues remain. These include food standards as a potential market entry barrier for food producers and distributors, limited food standard harmonization, and communication challenges of food attribute assurance (e.g., consumers’ signal processing, signal use and trust). The syntheses presented in this study contributes to stakeholders’ (e.g., supply chain actors, scientists, policy makers) improved understanding about the components of the credence food system and their integration as well as the drivers for change in this system.

There are currently two robust traditions in philosophy dealing with doxastic attitudes: the tradition that is concerned primarily with all-or-nothing belief, and the tradition that is concerned primarily with degree of belief or credence. This paper concerns the relationship between belief and credence for a rational agent, and is directed at those who may have hoped that the notion of belief can either be reduced to credence or eliminated altogether when characterizing the norms governing ideally rational agents. It presents a puzzle which lends support to two theses. First, that there is no formal reduction of a rational agent's beliefs to her credences, because belief and credence are each responsive to different features of a body of evidence. Second, that if our traditional understanding of our practices of holding each other responsible is correct, then belief has a distinctive role to play, even for ideally rational agents, that cannot be played by credence. The question of which avenues remain for the credence-only theorist is considered. © 2013 Springer Science+Business Media Dordrecht.

Patients with Type 2 Diabetes (T2D) are at risk of developing macrovascular (cardiac, cerebrovascular, peripheral arterial disease) and microvascular (nephropathy, neuropathy, retinopathy) complications. Glycemic control improves only microvascular outcomes. However, some SGLT-2 inhibitors and GLP1-R agonists have proven beneficial in macrovascular conditions. Canagliflozin is an SGLT2 inhibitor that provides sustained reductions in HbA1c, blood pressure and weight. Remarkably, as CANVAS program and CREDENCE trial demonstrated, canagliflozin promotes significant reductions in the frequency of atherosclerotic cardiovascular events, hospitalizations for heart failure and renal outcomes. In addition, real-world studies have confirmed the results of clinical trials in clinical practice. Therefore, canagliflozin should be considered a first-line therapy in the management of T2D patients in order to reduce both micro- and macrovascular complications. [ABSTRACT FROM AUTHOR]

As part of society, religious organizations are exposed to contextual conditions and challenges. However, adapting to external conditions is an act of balance since too much compromising may risk having a negative effect on employees’ perception of organizational authenticity and, in turn, employees’ well-being and attitudes toward work. In this study, we examined how specific characteristics of the work, in terms of job demands (role conflict and emotional demands) and job resources (influence at work and social community at work), as well as employees’ credence in the organization’s ability to respond to change, relate to employee well-being within the Church of Sweden. In total 2,112 employees (58% participation rate) answered a web-based survey. The results of regression analyses showed that job resources and credence in the organization’s ability to respond to change provided a clear contribution to the explanation of variance in work engagement and, especially, job satisfaction. However, the contribution of job demands was less clear. Moreover, to further the understanding of the association between employees’ credence in the organization’s ability to respond to change and employee well-being, the mediating effect of job resources was tested. The results showed that the association between credence and well-being is in part mediated by job resources. In sum, the study demonstrate that employees’ credence in the organization’s ability to respond to change is important to consider for understanding employee well-being within religious organizations. In conclusion, our study suggest that organizations that are built up on strong values and institutionalized beliefs, such as religious and faith-based organizations, need to tread carefully in the process of adapting to conformal pressure for change. This, since the actions and choices of the organization are important for employees’ credence in the organization and, in turn, employee well-being. Implications and recommendations for future research are discussed.

Introduction: On the basis of reductions in diabetic kidney disease (DKD) progression and major adverse cardiovascular events observed in the landmark CREDENCE trial, canagliflozin 100 mg received an extension to its EU marketing authorisation in July 2020 to include the treatment of DKD in people with type 2 diabetes mellitus (T2DM) making it the first pharmacological therapy to receive regulatory authorisation for treatment of DKD since the RENAAL and IDNT trials in nearly 20 years. Efficient allocation of limited healthcare resources requires evaluation not only of clinical safety and efficacy but also economic consequences. The study aim was to estimate the cost-effectiveness of canagliflozin when added to current standard of care (SoC) versus SoC alone from the perspective of the NHS in England. Methods: A microsimulation model was developed using patient-level data from CREDENCE, including risk equations for the key clinical outcomes of start of dialysis, hospitalisation for heart failure, nonfatal myocardial infarction, nonfatal stroke, and all-cause mortality. DKD progression was modelled using estimated glomerular filtration rate and urinary albumin-to-creatinine ratio evolution equations. Risk for kidney transplant was sourced from UK-specific sources given the near absence of events in CREDENCE. Patient characteristics and treatment effects were sourced from CREDENCE. Unit costs (£2019) and disutility weights were sourced from the literature and discounted at 3.5% annually. The time horizon was 10 years in the base case, and sensitivity analysis was performed. Results: Canagliflozin was associated with sizable gains in life-years and quality-adjusted life-year (QALYs) over 10 years, with gains increasing with simulation duration. Cost offsets associated with reductions in cardiovascular and renal complications were sufficient to achieve overall net cost savings. The findings were generally confirmed in the sensitivity analyses. Conclusion: Model results suggest that adding canagliflozin 100 mg to SoC can improve patient outcomes while reducing overall net costs from the NHS perspective in England. Trial Registration: ClinicalTrials.gov identifier, NCT02065791. [ABSTRACT FROM AUTHOR]

One defense of the "steadfast" position in cases of peer disagreement appeals to the idea that it's rational for you to remain deeply agnostic about relevant propositions concerning your peer's judgment, that is, to assign no credence value at all to such propositions. Thus, according to this view, since you need not assign any value to the proposition that your peer's judgment is likely to be correct, you need not conciliate, since you can remain deeply agnostic on the question of how the likelihood of your peer's judgment bears on the likelihood of your own. This paper argues that the case for deep agnosticism as a response to peer disagreement fails. Deep agnosticism (as a general thesis) implies that it is sometimes permissible to withhold judgment about whether there is a non-zero chance of a proposition's being true. However, in cases of disagreement where deep agnosticism is supposed to support the steadfast position, such withholding isn't rational. This is because of constraints placed on rational credence by objective probability or chance, which ensure that rational credence adequately reflects strength of evidence. [ABSTRACT FROM AUTHOR]

As part of society, religious organizations are exposed to contextual conditions and challenges. However, adapting to external conditions is an act of balance since too much compromising may risk having a negative effect on employees' perception of organizational authenticity and, in turn, employees' well-being and attitudes toward work. In this study, we examined how specific characteristics of the work, in terms of job demands (role conflict and emotional demands) and job resources (influence at work and social community at work), as well as employees' credence in the organization's ability to respond to change, relate to employee well-being within the Church of Sweden. In total 2,112 employees (58% participation rate) answered a web-based survey. The results of regression analyses showed that job resources and credence in the organization's ability to respond to change provided a clear contribution to the explanation of variance in work engagement and, especially, job satisfaction. However, the contribution of job demands was less clear. Moreover, to further the understanding of the association between employees' credence in the organization's ability to respond to change and employee well-being, the mediating effect of job resources was tested. The results showed that the association between credence and well-being is in part mediated by job resources. In sum, the study demonstrate that employees' credence in the organization's ability to respond to change is important to consider for understanding employee well-being within religious organizations. In conclusion, our study suggest that organizations that are built up on strong values and institutionalized beliefs, such as religious and faith-based organizations, need to tread carefully in the process of adapting to conformal pressure for change. This, since the actions and choices of the organization are important for employees' credence in the organization and, in turn, employee well-being. Implications and recommendations for future research are discussed. [ABSTRACT FROM AUTHOR]

This paper offers practical advice about how to interact with machines that we have reason to believe could have minds. I argue that we should approach these interactions by assigning credences to judgements about whether the machines in question can think. We should treat the premises of philosophical arguments about whether these machines can think as offering evidence that may increase or reduce these credences. I describe two cases in which you should refrain from doing as your favored philosophical view about thinking machines suggests. Even if you believe that machines are mindless, you should acknowledge that treating them as if they are mindless risks wronging them. Suppose your considered philosophical view that a machine has a mind leads you to consider dating it. You may have reason to regret that decision should these dates lead on to a life-long relationship with a mindless machine. In the paper's final section, I suggest that building a machine that is capable of performing all intelligent human behavior should produce a general increase in confidence that machines can think. Any reasonable judge should count this feat as evidence in favor of machines having minds. This rational nudge could lead to broad acceptance of the idea that machines can think. [ABSTRACT FROM AUTHOR]

The 5th Cardiovascular Outcome Trial (CVOT) Summit was held in Munich on October 24th–25th, 2019. As in previous years, this summit served as a reference meeting for in-depth discussions on the topic of recently completed and presented CVOTs. This year, focus was placed on the CVOTs CAROLINA, CREDENCE, DAPA-HF, REWIND, and PIONEER-6. Trial implications for diabetes management and the impact on new treatment algorithms were highlighted for diabetologists, cardiologists, endocrinologists, nephrologists, and general practitioners. Discussions evolved from CVOTs to additional therapy options for heart failure (ARNI), knowledge gained for the treatment and prevention of heart failure and diabetic kidney disease in populations with and without diabetes, particularly using SGLT-2 inhibitors and GLP-1 receptor agonists. Furthermore, the ever increasing impact of CVOTs and substances tested for primary prevention and primary care was discussed. The 6th Cardiovascular Outcome Trial Summit will be held in Munich on October 29th–30th, 2020 (https://www.cvot.org). [ABSTRACT FROM AUTHOR]

[Vichian resonances in Leopardi’s Essay on the popular errors of the ancient people]. This paper aims to show the influence of Vico’s thought in Leopardi’sEssay on the popular errors of the ancient people. Such an influence is evident:in particular, Leopardi resumes Vico’s theory on Truth and the emergence of Belief. There are also differences between the two authors about the criticism they both address to the educational system. Furthermore, both Leopardi and Vico wrote about the cognitive process shared by children and primitive men characterized by wonder and curiosity.

In the climate change context, consumers are often urged to reduce meat consumption because of associated greenhouse gas emissions. However, it is unclear if consumers would pay more for meat with lower carbon footprint, among other credence factors. This paper reports one of the first studies to identify willingness-to-pay for meat that has been carbon-footprint-labelled as an attribute. Four discrete choice experiments are conducted about meat preferences for beef, chicken, lamb and pork, on 1,200 Australian respondents. The results show that credence factors remain less important to most consumers than intrinsic meat properties. Carbon footprint is non-significant in the estimated mixed logit models. Latent class analyses reveal that only one (representing 21% of consumers) out of three classes places high importance on carbon footprint. [ABSTRACT FROM AUTHOR]